Chemicals
Showing 25351–25500 of 41137 results
-
Lithocholic acid is a secondary bile acid that has been shown to cause cholestasis in animal models and has also been implicated in carcinogenesis.{32395,10150} It is produced from chenodeoxycholic acid by bacterial action in the colon and can be conjugated with glycine or taurine. Whereas in normal colonic epithelium lithocholic acid promotes apoptosis, it has been shown to suppress apoptosis in pre-malignant colonic epithelium in the presence of a carcinogen.{32394} Lithocholic acid can activate the pregnane X receptor and the vitamin D receptor, which may serve as a biological sensor to regulate lithocholic acid-induced toxicity.{10150,32396,16793}
Brand:CaymanSKU:20253 -Available on backorder
Lithocholic acid 3-sulfate is a metabolite of the secondary bile acid lithocholic acid (Item No. 20253).{43814} It is water soluble and the primary form of lithocholic acid in the bile duct. Lithocholic acid 3-sulfate forms a complex with calcium in vitro.{37658} Biliary secretion of lithocholic acid 3-sulfate is increased in a rat model of diabetes induced by streptozotocin (Item No. 13104).{37659}
Brand:CaymanSKU:20676 -Available on backorder
Lithocholic acid 3-sulfate is a metabolite of the secondary bile acid lithocholic acid (Item No. 20253).{43814} It is water soluble and the primary form of lithocholic acid in the bile duct. Lithocholic acid 3-sulfate forms a complex with calcium in vitro.{37658} Biliary secretion of lithocholic acid 3-sulfate is increased in a rat model of diabetes induced by streptozotocin (Item No. 13104).{37659}
Brand:CaymanSKU:20676 -Available on backorder
Lithocholic acid 3-sulfate is a metabolite of the secondary bile acid lithocholic acid (Item No. 20253).{43814} It is water soluble and the primary form of lithocholic acid in the bile duct. Lithocholic acid 3-sulfate forms a complex with calcium in vitro.{37658} Biliary secretion of lithocholic acid 3-sulfate is increased in a rat model of diabetes induced by streptozotocin (Item No. 13104).{37659}
Brand:CaymanSKU:20676 -Available on backorder
Lithocholic acid is a secondary bile acid that has been shown to cause cholestasis in animal models and has also been implicated in carcinogenesis.{32395,10150} It is produced from chenodeoxycholic acid (Item No. 10011286) by bacterial action in the colon and can be conjugated with glycine or taurine. Whereas in normal colonic epithelium lithocholic acid promotes apoptosis, it has been shown to suppress apoptosis in pre-malignant colonic epithelium in the presence of a carcinogen.{32394} Lithocholic acid can activate the pregnane X receptor and the vitamin D receptor, which may serve as a biological sensor to regulate lithocholic acid-induced toxicity.{32396,10150,16793} Lithocholic Acid MaxSpec® standard is a quantitative grade standard of Lithocholic Acid (Item No. 20253) that has been prepared specifically for mass spectrometry and related applications where quantitative reproducibility is required. The solution has been prepared gravimetrically and is supplied in a deactivated glass ampule sealed under argon. The concentration was verified by comparison to an independently prepared calibration standard. This Lithocholic Acid MaxSpec® standard is guaranteed to meet identity, purity, stability, and concentration specifications and is provided with a batch-specific certificate of analysis. Ongoing stability testing is performed to ensure the concentration remains accurate throughout the shelf life of the product. Note: The amount of solution added to the vial is in excess of the listed amount. Therefore, it is necessary to accurately measure volumes for preparation of calibration standards. Follow recommended storage and handling conditions to maintain product quality.
Brand:CaymanSKU:31353 - 100 µgAvailable on backorder
Lithocholic acid-d4 is intended for use as an internal standard for the quantification of lithocholic acid (Item No. 20253) by GC- or LC-MS. Lithocholic acid is a secondary bile acid that has been shown to cause cholestasis in animal models and has also been implicated in carcinogenesis.{32395,10150} It is produced from chenodeoxycholic acid by bacterial action in the colon and can be conjugated with glycine or taurine. Whereas in normal colonic epithelium lithocholic acid promotes apoptosis, it has been shown to suppress apoptosis in pre-malignant colonic epithelium in the presence of a carcinogen.{32394} Lithocholic acid can activate the pregnane X receptor and the vitamin D receptor, which may serve as a biological sensor to regulate lithocholic acid-induced toxicity.{32396,10150,16793}
Brand:CaymanSKU:20831 -Out of stock
Lithocholic acid-d4 is intended for use as an internal standard for the quantification of lithocholic acid (Item No. 20253) by GC- or LC-MS. Lithocholic acid is a secondary bile acid that has been shown to cause cholestasis in animal models and has also been implicated in carcinogenesis.{32395,10150} It is produced from chenodeoxycholic acid by bacterial action in the colon and can be conjugated with glycine or taurine. Whereas in normal colonic epithelium lithocholic acid promotes apoptosis, it has been shown to suppress apoptosis in pre-malignant colonic epithelium in the presence of a carcinogen.{32394} Lithocholic acid can activate the pregnane X receptor and the vitamin D receptor, which may serve as a biological sensor to regulate lithocholic acid-induced toxicity.{32396,10150,16793}
Brand:CaymanSKU:20831 -Out of stock
Lithocholic acid-d4 is intended for use as an internal standard for the quantification of lithocholic acid (Item No. 20253) by GC- or LC-MS. Lithocholic acid is a secondary bile acid that has been shown to cause cholestasis in animal models and has also been implicated in carcinogenesis.{32395,10150} It is produced from chenodeoxycholic acid by bacterial action in the colon and can be conjugated with glycine or taurine. Whereas in normal colonic epithelium lithocholic acid promotes apoptosis, it has been shown to suppress apoptosis in pre-malignant colonic epithelium in the presence of a carcinogen.{32394} Lithocholic acid can activate the pregnane X receptor and the vitamin D receptor, which may serve as a biological sensor to regulate lithocholic acid-induced toxicity.{32396,10150,16793}
Brand:CaymanSKU:20831 -Out of stock
Lithocholic acid-d4 is intended for use as an internal standard for the quantification of lithocholic acid (Item No. 20253) by GC- or LC-MS. Lithocholic acid is a secondary bile acid that has been shown to cause cholestasis in animal models and has also been implicated in carcinogenesis.{32395,10150} It is produced from chenodeoxycholic acid by bacterial action in the colon and can be conjugated with glycine or taurine. Whereas in normal colonic epithelium lithocholic acid promotes apoptosis, it has been shown to suppress apoptosis in pre-malignant colonic epithelium in the presence of a carcinogen.{32394} Lithocholic acid can activate the pregnane X receptor and the vitamin D receptor, which may serve as a biological sensor to regulate lithocholic acid-induced toxicity.{32396,10150,16793}
Brand:CaymanSKU:20831 -Out of stock
Lithocholic acid-d4 is intended for use as an internal standard for the quantification of lithocholic acid (Item No. 20253) by GC- or LC-MS. Lithocholic acid is a secondary bile acid that has been shown to cause cholestasis in animal models and has also been implicated in carcinogenesis.{32395,10150} It is produced from chenodeoxycholic acid (Item No. 10011286) by bacterial action in the colon and can be conjugated with glycine or taurine. Whereas in normal colonic epithelium lithocholic acid promotes apoptosis, it has been shown to suppress apoptosis in pre-malignant colonic epithelium in the presence of a carcinogen.{32394} Lithocholic acid can activate the pregnane X receptor and the vitamin D receptor, which may serve as a biological sensor to regulate lithocholic acid-induced toxicity.{10150,32396,16793} Lithocholic acid-d4 MaxSpec® standard is a quantitative grade standard of lithocholic acid-d4 (Item No. 20831) that has been prepared specifically for mass spectrometry and related applications where quantitative reproducibility is required. The solution has been prepared gravimetrically and is supplied in a deactivated glass ampule sealed under argon. The concentration was verified by comparison to an independently prepared calibration standard. This lithocholic acid-d4 MaxSpec® standard is guaranteed to meet identity, purity, stability, and concentration specifications and is provided with a batch-specific certificate of analysis. Ongoing stability testing is performed to ensure the concentration remains accurate throughout the shelf life of the product. Note: The amount of solution added to the vial is in excess of the listed amount. Therefore, it is necessary to accurately measure volumes for preparation of calibration standards. Follow recommended storage and handling conditions to maintain product quality.
Brand:CaymanSKU:31354 - 100 µgAvailable on backorder
Lixivaptan is a nonpeptide antagonist of vasopressin V2 receptors (Ki = 2.3 nM).{34309} It is 100-fold selective for V2 over V1a.{27294} Formulations containing lixivaptan decrease urinary excretion of aquaporin-2 in patients with chronic heart failure and increase serum sodium levels in patients with hyponatremia due to congestive heart failure.{34307,34308}
Brand:CaymanSKU:21511 -Out of stock
Lixivaptan is a nonpeptide antagonist of vasopressin V2 receptors (Ki = 2.3 nM).{34309} It is 100-fold selective for V2 over V1a.{27294} Formulations containing lixivaptan decrease urinary excretion of aquaporin-2 in patients with chronic heart failure and increase serum sodium levels in patients with hyponatremia due to congestive heart failure.{34307,34308}
Brand:CaymanSKU:21511 -Out of stock
Lixivaptan is a nonpeptide antagonist of vasopressin V2 receptors (Ki = 2.3 nM).{34309} It is 100-fold selective for V2 over V1a.{27294} Formulations containing lixivaptan decrease urinary excretion of aquaporin-2 in patients with chronic heart failure and increase serum sodium levels in patients with hyponatremia due to congestive heart failure.{34307,34308}
Brand:CaymanSKU:21511 -Out of stock
LJH685 is an inhibitor of p90 ribosomal S6 kinases (RSKs, also known as MAP kinase-activated protein kinases, or MAPKAPKs) that inhibits RSK1, 2, and 3 in vitro with IC50 values of 6, 5, and 4 nM, respectively.{33573} It is selective for RSKs over a panel of 96 other kinases. LJH685 blocks RSK activity in cells, preventing phosphorylation of y-box-binding protein 1 on Ser102.{33573} The inhibition of RSK activity correlates with antiproliferative effects in MAPK pathway-dependent cancer cell lines, but only in an anchorage-independent growth setting.{33573}
Brand:CaymanSKU:19913 -Available on backorder
LJH685 is an inhibitor of p90 ribosomal S6 kinases (RSKs, also known as MAP kinase-activated protein kinases, or MAPKAPKs) that inhibits RSK1, 2, and 3 in vitro with IC50 values of 6, 5, and 4 nM, respectively.{33573} It is selective for RSKs over a panel of 96 other kinases. LJH685 blocks RSK activity in cells, preventing phosphorylation of y-box-binding protein 1 on Ser102.{33573} The inhibition of RSK activity correlates with antiproliferative effects in MAPK pathway-dependent cancer cell lines, but only in an anchorage-independent growth setting.{33573}
Brand:CaymanSKU:19913 -Available on backorder
LJH685 is an inhibitor of p90 ribosomal S6 kinases (RSKs, also known as MAP kinase-activated protein kinases, or MAPKAPKs) that inhibits RSK1, 2, and 3 in vitro with IC50 values of 6, 5, and 4 nM, respectively.{33573} It is selective for RSKs over a panel of 96 other kinases. LJH685 blocks RSK activity in cells, preventing phosphorylation of y-box-binding protein 1 on Ser102.{33573} The inhibition of RSK activity correlates with antiproliferative effects in MAPK pathway-dependent cancer cell lines, but only in an anchorage-independent growth setting.{33573}
Brand:CaymanSKU:19913 -Available on backorder
LJH685 is an inhibitor of p90 ribosomal S6 kinases (RSKs, also known as MAP kinase-activated protein kinases, or MAPKAPKs) that inhibits RSK1, 2, and 3 in vitro with IC50 values of 6, 5, and 4 nM, respectively.{33573} It is selective for RSKs over a panel of 96 other kinases. LJH685 blocks RSK activity in cells, preventing phosphorylation of y-box-binding protein 1 on Ser102.{33573} The inhibition of RSK activity correlates with antiproliferative effects in MAPK pathway-dependent cancer cell lines, but only in an anchorage-independent growth setting.{33573}
Brand:CaymanSKU:19913 -Available on backorder
LJI308 is a selective and potent inhibitor of the p90 ribosomal S6 kinase (RSK) family with IC50 values ranging from 4 to 13 nM for RSK isoforms 1-3.{33573,39058} In a panel of 442 kinases, LJI308 is selective for RSK1, RSK3, and RSK4. It also inhibits S6K1, MEK4, and HIP in the low micromolar range but had no effect on other kinases tested.{33573} LJI308 also reduces phosphorylation of Y-box-binding protein (YB1) in MDA-MB-231 cells bearing activating mutations in the MAPK signaling pathway (EC50 = 0.21 μM) and reduces H358 growth in soft agar and colony forming assays.
Brand:CaymanSKU:19924 -Available on backorder
LJI308 is a selective and potent inhibitor of the p90 ribosomal S6 kinase (RSK) family with IC50 values ranging from 4 to 13 nM for RSK isoforms 1-3.{33573,39058} In a panel of 442 kinases, LJI308 is selective for RSK1, RSK3, and RSK4. It also inhibits S6K1, MEK4, and HIP in the low micromolar range but had no effect on other kinases tested.{33573} LJI308 also reduces phosphorylation of Y-box-binding protein (YB1) in MDA-MB-231 cells bearing activating mutations in the MAPK signaling pathway (EC50 = 0.21 μM) and reduces H358 growth in soft agar and colony forming assays.
Brand:CaymanSKU:19924 -Available on backorder
LJI308 is a selective and potent inhibitor of the p90 ribosomal S6 kinase (RSK) family with IC50 values ranging from 4 to 13 nM for RSK isoforms 1-3.{33573,39058} In a panel of 442 kinases, LJI308 is selective for RSK1, RSK3, and RSK4. It also inhibits S6K1, MEK4, and HIP in the low micromolar range but had no effect on other kinases tested.{33573} LJI308 also reduces phosphorylation of Y-box-binding protein (YB1) in MDA-MB-231 cells bearing activating mutations in the MAPK signaling pathway (EC50 = 0.21 μM) and reduces H358 growth in soft agar and colony forming assays.
Brand:CaymanSKU:19924 -Available on backorder
LJI308 is a selective and potent inhibitor of the p90 ribosomal S6 kinase (RSK) family with IC50 values ranging from 4 to 13 nM for RSK isoforms 1-3.{33573,39058} In a panel of 442 kinases, LJI308 is selective for RSK1, RSK3, and RSK4. It also inhibits S6K1, MEK4, and HIP in the low micromolar range but had no effect on other kinases tested.{33573} LJI308 also reduces phosphorylation of Y-box-binding protein (YB1) in MDA-MB-231 cells bearing activating mutations in the MAPK signaling pathway (EC50 = 0.21 μM) and reduces H358 growth in soft agar and colony forming assays.
Brand:CaymanSKU:19924 -Available on backorder
LL-37 is a cationic and α-helical antimicrobial peptide expressed in human bone marrow, testis, granulocytes, and gingival epithelium and is upregulated in psoriatic lesions.{41499} It inhibits growth of Gram-positive E. coli D21 and Gram-negative B. megatarium in a concentration-dependent manner and LL-37 expression is induced in A549 epithelial cells, alveolar macrophages, neutrophils, and monocyte-derived macrophages following M. tuberculosis infection.{41499,17198,41500} LL-37 binds sheep erythrocytes coated with S. minnesota Re-LPS and induces agglutination with a minimal agglutinating concentration (MAC) of 12.1 μg/ml.{41501} It is a chemoattractant for, and can induce calcium mobilization in, human monocytes, neutrophils, and T cells that naturally express formyl peptide receptor-like 1 (FPRL1) and FPRL1-transfected HEK293 cells.{41502} LL-37 (10-15 μM) pretreatment of dengue virus type 2 (DENV-2) reduces its infectivity as well as levels of viral genomic RNA and NS1 antigen.{41503} In vivo, LL-37 inhibits cecal ligation and puncture-induced caspase-1 activation and pyroptosis of peritoneal macrophages, reduces levels of the inflammatory cytokines IL-1β, IL-6, and TNF-α, and improves survival in polybacterial septic mice.{41504}
Brand:CaymanSKU:24461 - 1 mgAvailable on backorder
LL-37 is a cationic and α-helical antimicrobial peptide expressed in human bone marrow, testis, granulocytes, and gingival epithelium and is upregulated in psoriatic lesions.{41499} It inhibits growth of Gram-positive E. coli D21 and Gram-negative B. megatarium in a concentration-dependent manner and LL-37 expression is induced in A549 epithelial cells, alveolar macrophages, neutrophils, and monocyte-derived macrophages following M. tuberculosis infection.{41499,17198,41500} LL-37 binds sheep erythrocytes coated with S. minnesota Re-LPS and induces agglutination with a minimal agglutinating concentration (MAC) of 12.1 μg/ml.{41501} It is a chemoattractant for, and can induce calcium mobilization in, human monocytes, neutrophils, and T cells that naturally express formyl peptide receptor-like 1 (FPRL1) and FPRL1-transfected HEK293 cells.{41502} LL-37 (10-15 μM) pretreatment of dengue virus type 2 (DENV-2) reduces its infectivity as well as levels of viral genomic RNA and NS1 antigen.{41503} In vivo, LL-37 inhibits cecal ligation and puncture-induced caspase-1 activation and pyroptosis of peritoneal macrophages, reduces levels of the inflammatory cytokines IL-1β, IL-6, and TNF-α, and improves survival in polybacterial septic mice.{41504}
Brand:CaymanSKU:24461 - 500 µgAvailable on backorder
LL-Z 1640-4 is a cis-enol resorcylic acid lactone that has been shown to exhibit both antiviral and antiprotozoan activity.{30734} While LL-Z 1640-4 is inactive against JNK/p38 kinase signaling, its companion antibiotic, (5Z)-7-oxo zeaenol (Item No. 17459), has been identified as an irreversible inhibitor of the MAPKKK, TAK1, blocking T cell activation.{30735} Thus, LL-Z 1640-4 is useful as negative control to help dissect the selectivity of this MAPKKK inhibitor.
Brand:CaymanSKU:-Available on backorder
LL-Z 1640-4 is a cis-enol resorcylic acid lactone that has been shown to exhibit both antiviral and antiprotozoan activity.{30734} While LL-Z 1640-4 is inactive against JNK/p38 kinase signaling, its companion antibiotic, (5Z)-7-oxo zeaenol (Item No. 17459), has been identified as an irreversible inhibitor of the MAPKKK, TAK1, blocking T cell activation.{30735} Thus, LL-Z 1640-4 is useful as negative control to help dissect the selectivity of this MAPKKK inhibitor.
Brand:CaymanSKU:-Available on backorder
Survivin (also known as baculoviral IAP repeat-containing protein 5 (BIRC5)) is a member of the inhibitor of apoptosis (IAP) family that interacts with and inhibits the apoptotic function of several proteins.{18220,12862} LLP-3 is a cell-permeable ligand of Survivin that blocks its interaction with Ran, resulting in the induction of apoptosis (IAP) in glioma stem cells (IC50 = 31 µM).{30789} It abolishes the growth of glioblastoma multiforme cell in spheres and in tumor slice cultures.{30789}
Brand:CaymanSKU:-Available on backorder
Survivin (also known as baculoviral IAP repeat-containing protein 5 (BIRC5)) is a member of the inhibitor of apoptosis (IAP) family that interacts with and inhibits the apoptotic function of several proteins.{18220,12862} LLP-3 is a cell-permeable ligand of Survivin that blocks its interaction with Ran, resulting in the induction of apoptosis (IAP) in glioma stem cells (IC50 = 31 µM).{30789} It abolishes the growth of glioblastoma multiforme cell in spheres and in tumor slice cultures.{30789}
Brand:CaymanSKU:-Available on backorder
LLY-283 is an inhibitor of protein arginine methyltransferase 5 (PRMT5; IC50 = 22 nM).{43789} It is selective for PRMT5 over a panel of 32 methyltransferases, including PRMT4, -6, and -7 at 1 μM. LLY-283 reduces symmetric demethylation of SmBB’ in MCF-7 cells (IC50 = 25 nM). It reduces proliferation of various breast, gastric, hematological, lung, skin, and ovarian cancer cell lines (IC50s = 3-30 nM). LLY-283 (20 mg/kg) inhibits tumor growth in an A375 mouse xenograft model. See the Structural Genomics Consortium (SGC) website for more information.
Brand:CaymanSKU:21596 -Out of stock
LLY-283 is an inhibitor of protein arginine methyltransferase 5 (PRMT5; IC50 = 22 nM).{43789} It is selective for PRMT5 over a panel of 32 methyltransferases, including PRMT4, -6, and -7 at 1 μM. LLY-283 reduces symmetric demethylation of SmBB’ in MCF-7 cells (IC50 = 25 nM). It reduces proliferation of various breast, gastric, hematological, lung, skin, and ovarian cancer cell lines (IC50s = 3-30 nM). LLY-283 (20 mg/kg) inhibits tumor growth in an A375 mouse xenograft model. See the Structural Genomics Consortium (SGC) website for more information.
Brand:CaymanSKU:21596 -Out of stock
LLY-283 is an inhibitor of protein arginine methyltransferase 5 (PRMT5; IC50 = 22 nM).{43789} It is selective for PRMT5 over a panel of 32 methyltransferases, including PRMT4, -6, and -7 at 1 μM. LLY-283 reduces symmetric demethylation of SmBB’ in MCF-7 cells (IC50 = 25 nM). It reduces proliferation of various breast, gastric, hematological, lung, skin, and ovarian cancer cell lines (IC50s = 3-30 nM). LLY-283 (20 mg/kg) inhibits tumor growth in an A375 mouse xenograft model. See the Structural Genomics Consortium (SGC) website for more information.
Brand:CaymanSKU:21596 -Out of stock
LLY-283 is an inhibitor of protein arginine methyltransferase 5 (PRMT5; IC50 = 22 nM).{43789} It is selective for PRMT5 over a panel of 32 methyltransferases, including PRMT4, -6, and -7 at 1 μM. LLY-283 reduces symmetric demethylation of SmBB’ in MCF-7 cells (IC50 = 25 nM). It reduces proliferation of various breast, gastric, hematological, lung, skin, and ovarian cancer cell lines (IC50s = 3-30 nM). LLY-283 (20 mg/kg) inhibits tumor growth in an A375 mouse xenograft model. See the Structural Genomics Consortium (SGC) website for more information.
Brand:CaymanSKU:21596 -Out of stock
SMYD2 is a lysine N-methyltransferase that methylates both histones and non-histone proteins, including p53 and retinoblastoma-associated protein.{21355,23894} LLY-507 is a cell-active, small molecule inhibitor of SMYD2 (IC50 = 15 nM).{16441} It has been shown to inhibit p53 lysine370 monomethylation in KYSE-150 esophageal squamous cell carcinoma cells stably expressing SMYD2 with an IC50 value of 0.6 µM.{16441} LLY-507 is >100-fold selective for SMYD2 over a panel of 27 protein methyltransferases and non-methyltransferase targets.{16441} See the Structural Genomics Consortium (SGC) website for more information.
Brand:CaymanSKU:-Out of stock
SMYD2 is a lysine N-methyltransferase that methylates both histones and non-histone proteins, including p53 and retinoblastoma-associated protein.{21355,23894} LLY-507 is a cell-active, small molecule inhibitor of SMYD2 (IC50 = 15 nM).{16441} It has been shown to inhibit p53 lysine370 monomethylation in KYSE-150 esophageal squamous cell carcinoma cells stably expressing SMYD2 with an IC50 value of 0.6 µM.{16441} LLY-507 is >100-fold selective for SMYD2 over a panel of 27 protein methyltransferases and non-methyltransferase targets.{16441} See the Structural Genomics Consortium (SGC) website for more information.
Brand:CaymanSKU:-Out of stock
SMYD2 is a lysine N-methyltransferase that methylates both histones and non-histone proteins, including p53 and retinoblastoma-associated protein.{21355,23894} LLY-507 is a cell-active, small molecule inhibitor of SMYD2 (IC50 = 15 nM).{16441} It has been shown to inhibit p53 lysine370 monomethylation in KYSE-150 esophageal squamous cell carcinoma cells stably expressing SMYD2 with an IC50 value of 0.6 µM.{16441} LLY-507 is >100-fold selective for SMYD2 over a panel of 27 protein methyltransferases and non-methyltransferase targets.{16441} See the Structural Genomics Consortium (SGC) website for more information.
Brand:CaymanSKU:-Out of stock
SMYD2 is a lysine N-methyltransferase that methylates both histones and non-histone proteins, including p53 and retinoblastoma-associated protein.{21355,23894} LLY-507 is a cell-active, small molecule inhibitor of SMYD2 (IC50 = 15 nM).{16441} It has been shown to inhibit p53 lysine370 monomethylation in KYSE-150 esophageal squamous cell carcinoma cells stably expressing SMYD2 with an IC50 value of 0.6 µM.{16441} LLY-507 is >100-fold selective for SMYD2 over a panel of 27 protein methyltransferases and non-methyltransferase targets.{16441} See the Structural Genomics Consortium (SGC) website for more information.
Brand:CaymanSKU:-Out of stock
LM11A-31 is a p75 neurotrophin receptor (p75NTR) ligand that inhibits nerve growth factor (NGF) binding to p75NTR-Fc (A2 = 1,192 nM).{37423} It inhibits DNA damage in and promotes survival of hippocampal neuronal cultures in a p75NTR- and concentration-dependent manner. LMA11A-31 also inhibits proNGF-induced cell death of mature oligodendrocytes. In vivo, LMA11A-31 (10-100 mg/kg) improves motor function and coordination in the weight-bearing open-field test and nonweight-bearing swim test and increases survival of oligodendrocytes in a mouse model of spinal contusion injury.{37424} It prevents and/or reverses atrophy of forebrain cholinergic neurites and cortical dystrophic neurites in Thy-1 hAPPLond/Swe and Tg2576 mice with mid- to late stage Alzheimer’s disease.{37425} It also reduces excessive alcohol self-administration in rats and decreases huntingtin (Htt) aggregate formation and striatal cholinergic degeneration in the R6/2 mouse model of Huntington’s disease.{37426,37427}
Brand:CaymanSKU:21982 -Out of stock
LM11A-31 is a p75 neurotrophin receptor (p75NTR) ligand that inhibits nerve growth factor (NGF) binding to p75NTR-Fc (A2 = 1,192 nM).{37423} It inhibits DNA damage in and promotes survival of hippocampal neuronal cultures in a p75NTR- and concentration-dependent manner. LMA11A-31 also inhibits proNGF-induced cell death of mature oligodendrocytes. In vivo, LMA11A-31 (10-100 mg/kg) improves motor function and coordination in the weight-bearing open-field test and nonweight-bearing swim test and increases survival of oligodendrocytes in a mouse model of spinal contusion injury.{37424} It prevents and/or reverses atrophy of forebrain cholinergic neurites and cortical dystrophic neurites in Thy-1 hAPPLond/Swe and Tg2576 mice with mid- to late stage Alzheimer’s disease.{37425} It also reduces excessive alcohol self-administration in rats and decreases huntingtin (Htt) aggregate formation and striatal cholinergic degeneration in the R6/2 mouse model of Huntington’s disease.{37426,37427}
Brand:CaymanSKU:21982 -Out of stock
LM11A-31 is a p75 neurotrophin receptor (p75NTR) ligand that inhibits nerve growth factor (NGF) binding to p75NTR-Fc (A2 = 1,192 nM).{37423} It inhibits DNA damage in and promotes survival of hippocampal neuronal cultures in a p75NTR- and concentration-dependent manner. LMA11A-31 also inhibits proNGF-induced cell death of mature oligodendrocytes. In vivo, LMA11A-31 (10-100 mg/kg) improves motor function and coordination in the weight-bearing open-field test and nonweight-bearing swim test and increases survival of oligodendrocytes in a mouse model of spinal contusion injury.{37424} It prevents and/or reverses atrophy of forebrain cholinergic neurites and cortical dystrophic neurites in Thy-1 hAPPLond/Swe and Tg2576 mice with mid- to late stage Alzheimer’s disease.{37425} It also reduces excessive alcohol self-administration in rats and decreases huntingtin (Htt) aggregate formation and striatal cholinergic degeneration in the R6/2 mouse model of Huntington’s disease.{37426,37427}
Brand:CaymanSKU:21982 -Out of stock
LM11A-31 is a p75 neurotrophin receptor (p75NTR) ligand that inhibits nerve growth factor (NGF) binding to p75NTR-Fc (A2 = 1,192 nM).{37423} It inhibits DNA damage in and promotes survival of hippocampal neuronal cultures in a p75NTR- and concentration-dependent manner. LMA11A-31 also inhibits proNGF-induced cell death of mature oligodendrocytes. In vivo, LMA11A-31 (10-100 mg/kg) improves motor function and coordination in the weight-bearing open-field test and nonweight-bearing swim test and increases survival of oligodendrocytes in a mouse model of spinal contusion injury.{37424} It prevents and/or reverses atrophy of forebrain cholinergic neurites and cortical dystrophic neurites in Thy-1 hAPPLond/Swe and Tg2576 mice with mid- to late stage Alzheimer’s disease.{37425} It also reduces excessive alcohol self-administration in rats and decreases huntingtin (Htt) aggregate formation and striatal cholinergic degeneration in the R6/2 mouse model of Huntington’s disease.{37426,37427}
Brand:CaymanSKU:21982 -Out of stock
LM22A-4 is a brain-derived neurotrophic factor (BDNF) mimetic and agonist of the receptor tropomyosin-related kinase B (TrkB; IC50 = 47 nM in a fluorescence anisotropy assay).{38767} It selectively inhibits BDNF binding to 3T3 cells expressing TrkB over those expressing TrkA, TrkC, or p75NTR. In vitro, LM22A-4 increases survival of hippocampal neurons via activation of TrkB as well as Akt and ERK downstream pro-survival signaling pathways. In vivo, LM22A-4 increases dwell time in an accelerating rotarod task, indicating improved motor learning in a rat model of traumatic brain injury. LM22A-4 restores TrkB phosphorylation in the medulla and pons and breathing frequency to wild-type levels in a mouse model of Rett syndrome when administered at a dose of 50 mg/kg.{38768} It reduces neurite degeneration, formation of intranuclear huntingtin aggregates, and improves downward climbing and grip strength in mouse models of Huntington’s disease.{38769} LM22A-4 (0.22 mg/kg) also improves limb swing speed and accelerates return to normal gait accuracy in a mouse model of hypoxic-ischemic stroke.{38770}
Brand:CaymanSKU:22082 -Out of stock
LM22A-4 is a brain-derived neurotrophic factor (BDNF) mimetic and agonist of the receptor tropomyosin-related kinase B (TrkB; IC50 = 47 nM in a fluorescence anisotropy assay).{38767} It selectively inhibits BDNF binding to 3T3 cells expressing TrkB over those expressing TrkA, TrkC, or p75NTR. In vitro, LM22A-4 increases survival of hippocampal neurons via activation of TrkB as well as Akt and ERK downstream pro-survival signaling pathways. In vivo, LM22A-4 increases dwell time in an accelerating rotarod task, indicating improved motor learning in a rat model of traumatic brain injury. LM22A-4 restores TrkB phosphorylation in the medulla and pons and breathing frequency to wild-type levels in a mouse model of Rett syndrome when administered at a dose of 50 mg/kg.{38768} It reduces neurite degeneration, formation of intranuclear huntingtin aggregates, and improves downward climbing and grip strength in mouse models of Huntington’s disease.{38769} LM22A-4 (0.22 mg/kg) also improves limb swing speed and accelerates return to normal gait accuracy in a mouse model of hypoxic-ischemic stroke.{38770}
Brand:CaymanSKU:22082 -Out of stock
LM22A-4 is a brain-derived neurotrophic factor (BDNF) mimetic and agonist of the receptor tropomyosin-related kinase B (TrkB; IC50 = 47 nM in a fluorescence anisotropy assay).{38767} It selectively inhibits BDNF binding to 3T3 cells expressing TrkB over those expressing TrkA, TrkC, or p75NTR. In vitro, LM22A-4 increases survival of hippocampal neurons via activation of TrkB as well as Akt and ERK downstream pro-survival signaling pathways. In vivo, LM22A-4 increases dwell time in an accelerating rotarod task, indicating improved motor learning in a rat model of traumatic brain injury. LM22A-4 restores TrkB phosphorylation in the medulla and pons and breathing frequency to wild-type levels in a mouse model of Rett syndrome when administered at a dose of 50 mg/kg.{38768} It reduces neurite degeneration, formation of intranuclear huntingtin aggregates, and improves downward climbing and grip strength in mouse models of Huntington’s disease.{38769} LM22A-4 (0.22 mg/kg) also improves limb swing speed and accelerates return to normal gait accuracy in a mouse model of hypoxic-ischemic stroke.{38770}
Brand:CaymanSKU:22082 -Out of stock
LM22A-4 is a brain-derived neurotrophic factor (BDNF) mimetic and agonist of the receptor tropomyosin-related kinase B (TrkB; IC50 = 47 nM in a fluorescence anisotropy assay).{38767} It selectively inhibits BDNF binding to 3T3 cells expressing TrkB over those expressing TrkA, TrkC, or p75NTR. In vitro, LM22A-4 increases survival of hippocampal neurons via activation of TrkB as well as Akt and ERK downstream pro-survival signaling pathways. In vivo, LM22A-4 increases dwell time in an accelerating rotarod task, indicating improved motor learning in a rat model of traumatic brain injury. LM22A-4 restores TrkB phosphorylation in the medulla and pons and breathing frequency to wild-type levels in a mouse model of Rett syndrome when administered at a dose of 50 mg/kg.{38768} It reduces neurite degeneration, formation of intranuclear huntingtin aggregates, and improves downward climbing and grip strength in mouse models of Huntington’s disease.{38769} LM22A-4 (0.22 mg/kg) also improves limb swing speed and accelerates return to normal gait accuracy in a mouse model of hypoxic-ischemic stroke.{38770}
Brand:CaymanSKU:22082 -Out of stock
LM22B-10 is an activator of neurotrophic tyrosine kinase receptor 2 (TrkB) and -3 (TrkC).{45544} It is selective for TrkB and TrkC over TrkA in NIH3T3 cells but does inhibit the serotonin (5-HT) receptor subtype 5-HT5A and the dopamine transporter by greater than 50% in a panel of 57 G protein-coupled peptide and nonpeptide receptors at 10 µM. LM22B-10 increases survival, neurite length, and dendritic spine density of primary mouse embryonic hippocampal neurons when used at a concentration of 1 µM. LM22B-10 (50 mg/kg i.p. in combination with an intranasal dose of 5 mg/kg per day) also increases hippocampal neuron dendritic spine density in aged mice.
Brand:CaymanSKU:29037 - 10 mgAvailable on backorder
LM22B-10 is an activator of neurotrophic tyrosine kinase receptor 2 (TrkB) and -3 (TrkC).{45544} It is selective for TrkB and TrkC over TrkA in NIH3T3 cells but does inhibit the serotonin (5-HT) receptor subtype 5-HT5A and the dopamine transporter by greater than 50% in a panel of 57 G protein-coupled peptide and nonpeptide receptors at 10 µM. LM22B-10 increases survival, neurite length, and dendritic spine density of primary mouse embryonic hippocampal neurons when used at a concentration of 1 µM. LM22B-10 (50 mg/kg i.p. in combination with an intranasal dose of 5 mg/kg per day) also increases hippocampal neuron dendritic spine density in aged mice.
Brand:CaymanSKU:29037 - 25 mgAvailable on backorder
LM22B-10 is an activator of neurotrophic tyrosine kinase receptor 2 (TrkB) and -3 (TrkC).{45544} It is selective for TrkB and TrkC over TrkA in NIH3T3 cells but does inhibit the serotonin (5-HT) receptor subtype 5-HT5A and the dopamine transporter by greater than 50% in a panel of 57 G protein-coupled peptide and nonpeptide receptors at 10 µM. LM22B-10 increases survival, neurite length, and dendritic spine density of primary mouse embryonic hippocampal neurons when used at a concentration of 1 µM. LM22B-10 (50 mg/kg i.p. in combination with an intranasal dose of 5 mg/kg per day) also increases hippocampal neuron dendritic spine density in aged mice.
Brand:CaymanSKU:29037 - 5 mgAvailable on backorder
LMI070 is an SMN2 splice modulator.{42746} It selectively enhances SMN2 splicing by stabilizing the complex formed by the U1 small nuclear ribonucleic protein (snRNP) and SMN2 pre-mRNA. LMI070 (3-30 mg/kg) increases the expression of the full-length SMN2 trancript and, at doses ranging from 0.3 to 30 mg/kg, increases SMN protein levels in the brain and spinal cord in the C/+ mouse model of spinal muscular atrophy (SMA).{42746,42747} It also increases survival of SMNΔ7 mice, a model of severe SMA, when administered at doses of 1 and 3 mg/kg.{42746}
Brand:CaymanSKU:26757 - 1 mgAvailable on backorder
LMI070 is an SMN2 splice modulator.{42746} It selectively enhances SMN2 splicing by stabilizing the complex formed by the U1 small nuclear ribonucleic protein (snRNP) and SMN2 pre-mRNA. LMI070 (3-30 mg/kg) increases the expression of the full-length SMN2 trancript and, at doses ranging from 0.3 to 30 mg/kg, increases SMN protein levels in the brain and spinal cord in the C/+ mouse model of spinal muscular atrophy (SMA).{42746,42747} It also increases survival of SMNΔ7 mice, a model of severe SMA, when administered at doses of 1 and 3 mg/kg.{42746}
Brand:CaymanSKU:26757 - 10 mgAvailable on backorder
LMI070 is an SMN2 splice modulator.{42746} It selectively enhances SMN2 splicing by stabilizing the complex formed by the U1 small nuclear ribonucleic protein (snRNP) and SMN2 pre-mRNA. LMI070 (3-30 mg/kg) increases the expression of the full-length SMN2 trancript and, at doses ranging from 0.3 to 30 mg/kg, increases SMN protein levels in the brain and spinal cord in the C/+ mouse model of spinal muscular atrophy (SMA).{42746,42747} It also increases survival of SMNΔ7 mice, a model of severe SMA, when administered at doses of 1 and 3 mg/kg.{42746}
Brand:CaymanSKU:26757 - 25 mgAvailable on backorder
LMI070 is an SMN2 splice modulator.{42746} It selectively enhances SMN2 splicing by stabilizing the complex formed by the U1 small nuclear ribonucleic protein (snRNP) and SMN2 pre-mRNA. LMI070 (3-30 mg/kg) increases the expression of the full-length SMN2 trancript and, at doses ranging from 0.3 to 30 mg/kg, increases SMN protein levels in the brain and spinal cord in the C/+ mouse model of spinal muscular atrophy (SMA).{42746,42747} It also increases survival of SMNΔ7 mice, a model of severe SMA, when administered at doses of 1 and 3 mg/kg.{42746}
Brand:CaymanSKU:26757 - 5 mgAvailable on backorder
Histone deacetylases (HDACs) catalyze the hydrolytic removal of acetyl groups from histone lysine residues, which commonly results in chromatin condensation and transcriptional repression.{12365,12366} LMK 235 is an HDAC inhibitor that selectively targets HDACs 4 and 5 (IC50s = 12 and 4 nM, respectively) over other HDACs (IC50s = 56, 320, 850, 880, and 1,280 for HDACs 6, 1, 11, 2, and 8, respectively).{30765} It displays enhanced cytotoxic effects against human cancer cell lines, compared to SAHA (Item No. 10009929) or trichostatin A (Item No. 89730).{30765} LMK 235 and derivatives inhibit the growth of the malarial parasite P. falciparum at multiple life cycle stages at nanomolar concentrations.{30764}
Brand:CaymanSKU:- Histone deacetylases (HDACs) catalyze the hydrolytic removal of acetyl groups from histone lysine residues, which commonly results in chromatin condensation and transcriptional repression.{12365,12366} LMK 235 is an HDAC inhibitor that selectively targets HDACs 4 and 5 (IC50s = 12 and 4 nM, respectively) over other HDACs (IC50s = 56, 320, 850, 880, and 1,280 for HDACs 6, 1, 11, 2, and 8, respectively).{30765} It displays enhanced cytotoxic effects against human cancer cell lines, compared to SAHA (Item No. 10009929) or trichostatin A (Item No. 89730).{30765} LMK 235 and derivatives inhibit the growth of the malarial parasite P. falciparum at multiple life cycle stages at nanomolar concentrations.{30764}
Brand:CaymanSKU:- Histone deacetylases (HDACs) catalyze the hydrolytic removal of acetyl groups from histone lysine residues, which commonly results in chromatin condensation and transcriptional repression.{12365,12366} LMK 235 is an HDAC inhibitor that selectively targets HDACs 4 and 5 (IC50s = 12 and 4 nM, respectively) over other HDACs (IC50s = 56, 320, 850, 880, and 1,280 for HDACs 6, 1, 11, 2, and 8, respectively).{30765} It displays enhanced cytotoxic effects against human cancer cell lines, compared to SAHA (Item No. 10009929) or trichostatin A (Item No. 89730).{30765} LMK 235 and derivatives inhibit the growth of the malarial parasite P. falciparum at multiple life cycle stages at nanomolar concentrations.{30764}
Brand:CaymanSKU:- Histone deacetylases (HDACs) catalyze the hydrolytic removal of acetyl groups from histone lysine residues, which commonly results in chromatin condensation and transcriptional repression.{12365,12366} LMK 235 is an HDAC inhibitor that selectively targets HDACs 4 and 5 (IC50s = 12 and 4 nM, respectively) over other HDACs (IC50s = 56, 320, 850, 880, and 1,280 for HDACs 6, 1, 11, 2, and 8, respectively).{30765} It displays enhanced cytotoxic effects against human cancer cell lines, compared to SAHA (Item No. 10009929) or trichostatin A (Item No. 89730).{30765} LMK 235 and derivatives inhibit the growth of the malarial parasite P. falciparum at multiple life cycle stages at nanomolar concentrations.{30764}
Brand:CaymanSKU:-
LMW-PTP inhibitor I is an inhibitor of low molecular weight phosphotyrosine protein phosphatase A (LMW-PTPA; IC50 = 0.8 µM).{34480} It is selective for LMW-PTPA over a panel of 15 protein tyrosine phosphatases but does inhibit LMW-PTPB activity by greater than 50% at 40 µM. LMW-PTP inhibitor I increases insulin-induced insulin receptor phosphorylation in HepG2 cells when used at a concentration of 10 µM. It improves glucose tolerance and decreases fasting plasma insulin levels in a mouse model of diet-induced obesity when administered at a dose of 50 mg/kg per day.
Brand:CaymanSKU:22277 -Out of stock
LMW-PTP inhibitor I is an inhibitor of low molecular weight phosphotyrosine protein phosphatase A (LMW-PTPA; IC50 = 0.8 µM).{34480} It is selective for LMW-PTPA over a panel of 15 protein tyrosine phosphatases but does inhibit LMW-PTPB activity by greater than 50% at 40 µM. LMW-PTP inhibitor I increases insulin-induced insulin receptor phosphorylation in HepG2 cells when used at a concentration of 10 µM. It improves glucose tolerance and decreases fasting plasma insulin levels in a mouse model of diet-induced obesity when administered at a dose of 50 mg/kg per day.
Brand:CaymanSKU:22277 -Out of stock
LMW-PTP inhibitor I is an inhibitor of low molecular weight phosphotyrosine protein phosphatase A (LMW-PTPA; IC50 = 0.8 µM).{34480} It is selective for LMW-PTPA over a panel of 15 protein tyrosine phosphatases but does inhibit LMW-PTPB activity by greater than 50% at 40 µM. LMW-PTP inhibitor I increases insulin-induced insulin receptor phosphorylation in HepG2 cells when used at a concentration of 10 µM. It improves glucose tolerance and decreases fasting plasma insulin levels in a mouse model of diet-induced obesity when administered at a dose of 50 mg/kg per day.
Brand:CaymanSKU:22277 -Out of stock
LMW-PTP inhibitor I is an inhibitor of low molecular weight phosphotyrosine protein phosphatase A (LMW-PTPA; IC50 = 0.8 µM).{34480} It is selective for LMW-PTPA over a panel of 15 protein tyrosine phosphatases but does inhibit LMW-PTPB activity by greater than 50% at 40 µM. LMW-PTP inhibitor I increases insulin-induced insulin receptor phosphorylation in HepG2 cells when used at a concentration of 10 µM. It improves glucose tolerance and decreases fasting plasma insulin levels in a mouse model of diet-induced obesity when administered at a dose of 50 mg/kg per day.
Brand:CaymanSKU:22277 -Out of stock
Lobaric acid is a depsidone metabolite that has been isolated from Stereocaulon lichen species with antioxidant, antiproliferative, antiviral, and enzyme inhibitory activites.{42123,42124,42125,42126,42127,42128} It scavenges superoxide radicals in a cell-free assay (IC50 = 97.9 μmol) and inhibits proliferation in a panel of leukemia, colorectal, gastric, breast, ovarian, prostate, pancreatic, and lung cancer cell lines (EC50s = 15.2-63.9 μg/ml).{42124,42125} Lobaric acid inhibits protein tyrosine phosphatase 1B (PTP1B; IC50 = 0.87 μM for the human recombinant enzyme) and production of 12(S)-HETE (Item No. 34570) by 12(S)-lipoxygenase (IC50 = 28.5 μM).{42127,42128} In vivo, lobaric acid (250 μM) decreases lesion number, but not lesion diameter, in tobacco leaves infected with tobacco mosaic virus (TMV).{42126}
Brand:CaymanSKU:25205 - 2.5 mgAvailable on backorder
Lobaric acid is a depsidone metabolite that has been isolated from Stereocaulon lichen species with antioxidant, antiproliferative, antiviral, and enzyme inhibitory activites.{42123,42124,42125,42126,42127,42128} It scavenges superoxide radicals in a cell-free assay (IC50 = 97.9 μmol) and inhibits proliferation in a panel of leukemia, colorectal, gastric, breast, ovarian, prostate, pancreatic, and lung cancer cell lines (EC50s = 15.2-63.9 μg/ml).{42124,42125} Lobaric acid inhibits protein tyrosine phosphatase 1B (PTP1B; IC50 = 0.87 μM for the human recombinant enzyme) and production of 12(S)-HETE (Item No. 34570) by 12(S)-lipoxygenase (IC50 = 28.5 μM).{42127,42128} In vivo, lobaric acid (250 μM) decreases lesion number, but not lesion diameter, in tobacco leaves infected with tobacco mosaic virus (TMV).{42126}
Brand:CaymanSKU:25205 - 500 µgAvailable on backorder
LOC14 is an inhibitor of protein disulfide isomerase (PDI; Kd = 62 nM).{28805} It inhibits PDI chaperone activity in an insulin aggregation assay when used at a concentration of 75 µM. LOC14 reduces PC12 cell death induced by the misfolded huntingtin protein mHTTQ103 (EC50 = 500 nM). It reduces medium spiny neuron (MSN) degeneration in a rat postnatal cortical brain slice model of mHTTQ73-induced Huntington’s disease.
Brand:CaymanSKU:-Available on backorder
LOC14 is an inhibitor of protein disulfide isomerase (PDI; Kd = 62 nM).{28805} It inhibits PDI chaperone activity in an insulin aggregation assay when used at a concentration of 75 µM. LOC14 reduces PC12 cell death induced by the misfolded huntingtin protein mHTTQ103 (EC50 = 500 nM). It reduces medium spiny neuron (MSN) degeneration in a rat postnatal cortical brain slice model of mHTTQ73-induced Huntington’s disease.
Brand:CaymanSKU:-Available on backorder
LOC14 is an inhibitor of protein disulfide isomerase (PDI; Kd = 62 nM).{28805} It inhibits PDI chaperone activity in an insulin aggregation assay when used at a concentration of 75 µM. LOC14 reduces PC12 cell death induced by the misfolded huntingtin protein mHTTQ103 (EC50 = 500 nM). It reduces medium spiny neuron (MSN) degeneration in a rat postnatal cortical brain slice model of mHTTQ73-induced Huntington’s disease.
Brand:CaymanSKU:-Available on backorder
LOC14 is an inhibitor of protein disulfide isomerase (PDI; Kd = 62 nM).{28805} It inhibits PDI chaperone activity in an insulin aggregation assay when used at a concentration of 75 µM. LOC14 reduces PC12 cell death induced by the misfolded huntingtin protein mHTTQ103 (EC50 = 500 nM). It reduces medium spiny neuron (MSN) degeneration in a rat postnatal cortical brain slice model of mHTTQ73-induced Huntington’s disease.
Brand:CaymanSKU:-Available on backorder
Lodoxamide is a potent agonist of GPR35 with an EC50 value of 1.61 nM in a β-arrestin-2 interaction assay using CHO-K1 cells expressing the human receptor.{38490} It inhibits histamine release induced by compound 48/80 (Item No. 22173), anti-IgE, or A23187 (Item No. 11016) in isolated rat peritoneal mast cells (IC50s = 0.1-50 µM) and inhibits A23187-induced calcium influx in mast cells.{38491} It reduces antigen-induced histamine release from rat conjunctival tissue by 46% in vitro when used at a concentration of 10 µg/ml.{38492} Lodoxamine (0.1 and 10%, w/v) reduces the immediate hypersensitivity response in rat conjunctiva in vivo in a dose-dependent manner and reduces mast cell degranulation in a topical ovalbumin challenge.{38492,38493} Formulations containing lodoxamide have been used in the treatment of vernal conjunctivitis and keratitis.
Brand:CaymanSKU:23994 - 100 mgAvailable on backorder
Lodoxamide is a potent agonist of GPR35 with an EC50 value of 1.61 nM in a β-arrestin-2 interaction assay using CHO-K1 cells expressing the human receptor.{38490} It inhibits histamine release induced by compound 48/80 (Item No. 22173), anti-IgE, or A23187 (Item No. 11016) in isolated rat peritoneal mast cells (IC50s = 0.1-50 µM) and inhibits A23187-induced calcium influx in mast cells.{38491} It reduces antigen-induced histamine release from rat conjunctival tissue by 46% in vitro when used at a concentration of 10 µg/ml.{38492} Lodoxamine (0.1 and 10%, w/v) reduces the immediate hypersensitivity response in rat conjunctiva in vivo in a dose-dependent manner and reduces mast cell degranulation in a topical ovalbumin challenge.{38492,38493} Formulations containing lodoxamide have been used in the treatment of vernal conjunctivitis and keratitis.
Brand:CaymanSKU:23994 - 25 mgAvailable on backorder
Lodoxamide is a potent agonist of GPR35 with an EC50 value of 1.61 nM in a β-arrestin-2 interaction assay using CHO-K1 cells expressing the human receptor.{38490} It inhibits histamine release induced by compound 48/80 (Item No. 22173), anti-IgE, or A23187 (Item No. 11016) in isolated rat peritoneal mast cells (IC50s = 0.1-50 µM) and inhibits A23187-induced calcium influx in mast cells.{38491} It reduces antigen-induced histamine release from rat conjunctival tissue by 46% in vitro when used at a concentration of 10 µg/ml.{38492} Lodoxamine (0.1 and 10%, w/v) reduces the immediate hypersensitivity response in rat conjunctiva in vivo in a dose-dependent manner and reduces mast cell degranulation in a topical ovalbumin challenge.{38492,38493} Formulations containing lodoxamide have been used in the treatment of vernal conjunctivitis and keratitis.
Brand:CaymanSKU:23994 - 250 mgAvailable on backorder
Lodoxamide is a potent agonist of GPR35 with an EC50 value of 1.61 nM in a β-arrestin-2 interaction assay using CHO-K1 cells expressing the human receptor.{38490} It inhibits histamine release induced by compound 48/80 (Item No. 22173), anti-IgE, or A23187 (Item No. 11016) in isolated rat peritoneal mast cells (IC50s = 0.1-50 µM) and inhibits A23187-induced calcium influx in mast cells.{38491} It reduces antigen-induced histamine release from rat conjunctival tissue by 46% in vitro when used at a concentration of 10 µg/ml.{38492} Lodoxamine (0.1 and 10%, w/v) reduces the immediate hypersensitivity response in rat conjunctiva in vivo in a dose-dependent manner and reduces mast cell degranulation in a topical ovalbumin challenge.{38492,38493} Formulations containing lodoxamide have been used in the treatment of vernal conjunctivitis and keratitis.
Brand:CaymanSKU:23994 - 50 mgAvailable on backorder
Lofepramine is a first generation tricyclic antidepressant that is extensively metabolized to desipramine.{32550} It potently inhibits serotonin and norepinephrine transporters (Kds = 70 and 5.4 nM, respectively) and less potently antagonizes serotonin, histamine, and muscarinic receptors.{22877,25803,25806}
Brand:CaymanSKU:20813 -Available on backorder
Lofepramine is a first generation tricyclic antidepressant that is extensively metabolized to desipramine.{32550} It potently inhibits serotonin and norepinephrine transporters (Kds = 70 and 5.4 nM, respectively) and less potently antagonizes serotonin, histamine, and muscarinic receptors.{22877,25803,25806}
Brand:CaymanSKU:20813 -Available on backorder
Lofepramine is a first generation tricyclic antidepressant that is extensively metabolized to desipramine.{32550} It potently inhibits serotonin and norepinephrine transporters (Kds = 70 and 5.4 nM, respectively) and less potently antagonizes serotonin, histamine, and muscarinic receptors.{22877,25803,25806}
Brand:CaymanSKU:20813 -Available on backorder
Lofepramine is a first generation tricyclic antidepressant that is extensively metabolized to desipramine.{32550} It potently inhibits serotonin and norepinephrine transporters (Kds = 70 and 5.4 nM, respectively) and less potently antagonizes serotonin, histamine, and muscarinic receptors.{22877,25803,25806}
Brand:CaymanSKU:20813 -Available on backorder
Lofexidine is an α2-adrenergic receptor agonist (Kd = 7.6 nM for rat cerebral cortex membranes) that has transient antihypertensive effects.{26103,26105} It is used in managing opioid withdrawal symptoms during detoxification from heroin (Item No. 9001543) and methadone.{26104,26101}
Brand:CaymanSKU:- Lofexidine is an α2-adrenergic receptor agonist (Kd = 7.6 nM for rat cerebral cortex membranes) that has transient antihypertensive effects.{26103,26105} It is used in managing opioid withdrawal symptoms during detoxification from heroin (Item No. 9001543) and methadone.{26104,26101}
Brand:CaymanSKU:- Lofexidine is an α2-adrenergic receptor agonist (Kd = 7.6 nM for rat cerebral cortex membranes) that has transient antihypertensive effects.{26103,26105} It is used in managing opioid withdrawal symptoms during detoxification from heroin (Item No. 9001543) and methadone.{26104,26101}
Brand:CaymanSKU:-
Loganic acid is an iridoid glycoside that has been found in C. mas and has diverse biological activities, including antidiabetic, antiadipogenic, anti-atherosclerotic, and anti-inflammatory properties.{46430,46431,46432,46433} Loganic acid (1 μM) stimulates glucagon-like peptide-1 (GLP-1) secretion by NCI H716 human enteroendocrine colorectal cancer cells.{46431} It inhibits dexamethasone-, 3-isobutyl-1-methylxanthine-, and insulin-induced differentiation of mouse 3T3-L1 fibroblasts into adipocytes when used at a concentration of 10 μg/ml.{46432} Loganic acid (20 mg/kg per day) decreases the plasma atherogenic index, a ratio of triglyceride to HDL cholesterol, and the cardiac risk ratio, a ratio of total cholesterol to HDL cholesterol, in a rabbit model of atherosclerosis induced by a cholesterol-rich diet.{46433} It also decreases IL-6, TNF-α, and oxidized LDL (oxLDL) plasma levels in the same model.
Brand:CaymanSKU:28402 - 10 mgAvailable on backorder
Loganic acid is an iridoid glycoside that has been found in C. mas and has diverse biological activities, including antidiabetic, antiadipogenic, anti-atherosclerotic, and anti-inflammatory properties.{46430,46431,46432,46433} Loganic acid (1 μM) stimulates glucagon-like peptide-1 (GLP-1) secretion by NCI H716 human enteroendocrine colorectal cancer cells.{46431} It inhibits dexamethasone-, 3-isobutyl-1-methylxanthine-, and insulin-induced differentiation of mouse 3T3-L1 fibroblasts into adipocytes when used at a concentration of 10 μg/ml.{46432} Loganic acid (20 mg/kg per day) decreases the plasma atherogenic index, a ratio of triglyceride to HDL cholesterol, and the cardiac risk ratio, a ratio of total cholesterol to HDL cholesterol, in a rabbit model of atherosclerosis induced by a cholesterol-rich diet.{46433} It also decreases IL-6, TNF-α, and oxidized LDL (oxLDL) plasma levels in the same model.
Brand:CaymanSKU:28402 - 25 mgAvailable on backorder
Loganic acid is an iridoid glycoside that has been found in C. mas and has diverse biological activities, including antidiabetic, antiadipogenic, anti-atherosclerotic, and anti-inflammatory properties.{46430,46431,46432,46433} Loganic acid (1 μM) stimulates glucagon-like peptide-1 (GLP-1) secretion by NCI H716 human enteroendocrine colorectal cancer cells.{46431} It inhibits dexamethasone-, 3-isobutyl-1-methylxanthine-, and insulin-induced differentiation of mouse 3T3-L1 fibroblasts into adipocytes when used at a concentration of 10 μg/ml.{46432} Loganic acid (20 mg/kg per day) decreases the plasma atherogenic index, a ratio of triglyceride to HDL cholesterol, and the cardiac risk ratio, a ratio of total cholesterol to HDL cholesterol, in a rabbit model of atherosclerosis induced by a cholesterol-rich diet.{46433} It also decreases IL-6, TNF-α, and oxidized LDL (oxLDL) plasma levels in the same model.
Brand:CaymanSKU:28402 - 5 mgAvailable on backorder
Loganic acid is an iridoid glycoside that has been found in C. mas and has diverse biological activities, including antidiabetic, antiadipogenic, anti-atherosclerotic, and anti-inflammatory properties.{46430,46431,46432,46433} Loganic acid (1 μM) stimulates glucagon-like peptide-1 (GLP-1) secretion by NCI H716 human enteroendocrine colorectal cancer cells.{46431} It inhibits dexamethasone-, 3-isobutyl-1-methylxanthine-, and insulin-induced differentiation of mouse 3T3-L1 fibroblasts into adipocytes when used at a concentration of 10 μg/ml.{46432} Loganic acid (20 mg/kg per day) decreases the plasma atherogenic index, a ratio of triglyceride to HDL cholesterol, and the cardiac risk ratio, a ratio of total cholesterol to HDL cholesterol, in a rabbit model of atherosclerosis induced by a cholesterol-rich diet.{46433} It also decreases IL-6, TNF-α, and oxidized LDL (oxLDL) plasma levels in the same model.
Brand:CaymanSKU:28402 - 50 mgAvailable on backorder
Loganin is an iridoid glycoside that has been found in C. fructus and has diverse biological activities.{32245,32247,57095,57096} It reduces hydrogen peroxide-induced apoptosis in SH-SY5Y cells when used at concentrations ranging from 0.25 to 12.5 µM.{32245} Loganin inhibits COX-1 activity (IC50 = 3.55 µM), as well as LPS-induced TNF-α formation (IC50 = 154.6 µM) in RAW 264.7 cells.{32247} In vivo, loganin (20 and 100 mg/kg) reduces food intake, blood glucose levels, and serum triglyceride levels, as well as increases serum HDL levels in db/db diabetic mice.{57095} It attenuates scopolamine-induced memory deficits in the Morris water maze and passive avoidance test in mice.{57096} Loganin (20 and 1,000 mg/kg) reduces serum and kidney advanced glycation end-product (AGE) and malondialdehyde (MDA) levels and improves renal function in a mouse model of diabetic nephropathy.{57097}
Brand:CaymanSKU:19997 -Available on backorder
Loganin is an iridoid glycoside that has been found in C. fructus and has diverse biological activities.{32245,32247,57095,57096} It reduces hydrogen peroxide-induced apoptosis in SH-SY5Y cells when used at concentrations ranging from 0.25 to 12.5 µM.{32245} Loganin inhibits COX-1 activity (IC50 = 3.55 µM), as well as LPS-induced TNF-α formation (IC50 = 154.6 µM) in RAW 264.7 cells.{32247} In vivo, loganin (20 and 100 mg/kg) reduces food intake, blood glucose levels, and serum triglyceride levels, as well as increases serum HDL levels in db/db diabetic mice.{57095} It attenuates scopolamine-induced memory deficits in the Morris water maze and passive avoidance test in mice.{57096} Loganin (20 and 1,000 mg/kg) reduces serum and kidney advanced glycation end-product (AGE) and malondialdehyde (MDA) levels and improves renal function in a mouse model of diabetic nephropathy.{57097}
Brand:CaymanSKU:19997 -Available on backorder